Scholarlink

Background <p>Immunotherapy has become a primary treatment for advanced non-small cell lung cancer (NSCLC), although drug resistance is inevitable. Radiotherapy enhances immunotherapy efficacy, particularly in early to mid-stage NSCLC. However, the synergistic effects of radiotherapy and immunotherapy in advanced NSCLC remain controversial.</p> Methods <p>We retrospectively analyzed data from 141 stage IV NSCLC patients treated with first-line immunotherapy or chemoimmunotherapy at Hangzhou Cancer Hospital. Patients were divided into groups receiving radiotherapy combined with immunotherapy versus immunotherapy alone. Progression-free survival (PFS) and overall survival (OS) were evaluated using the Cox regression method. Subgroup Cox regression analyses were performed to optimize the combination regimens.</p> Results <p>The combined therapy group showed longer PFS (16.9 vs. 8.49 months, HR 0.57, <i>p</i> = 0.006) and OS (69.93 vs. 24.62 months, HR 0.60, <i>p</i> = 0.04). Subgroup analysis indicated that non-squamous NSCLC patients without immunotherapy rechallenge benefited most. Radiotherapy added to immunotherapy in lung or brain metastases showed a trend toward improved PFS (lung: 19.34 vs. 6.03 months, HR 0.62, <i>p</i> = 0.30; brain: 22.72 vs. 7.80 months, HR 0.59, <i>p</i> = 0.29). Concurrent (HR 0.41, <i>p</i> = 0.02) or consolidation radiotherapy (HR 0.32, <i>p</i> = 0.003) during immunotherapy offered greater PFS benefits than symptom-relief radiotherapy. Both stereotactic body radiotherapy and conventional radiotherapy yielded similar survival outcomes. Incidence of grade 3 or higher pneumonia post-lung-radiotherapy was 3.45%.</p> Conclusions <p>Our study highlights the synergistic efficacy of combining radiotherapy with immunotherapy in advanced NSCLC. Optimizing patient selection, targeting specific sites, effective timing, and tailored radiotherapy regimens significantly improved PFS and OS, providing crucial insights for enhancing clinical outcomes in advanced NSCLC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Synergistic efficacy of radiotherapy and immunotherapy enhances clinical outcomes in patients with advanced non-small cell lung cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月24日

查看全文
  • Jiafeng Liang,
  • Lucheng Zhu,
  • Kan Wu,
  • Minna Zhang,
  • Yi Tang,
  • Kaicheng Pan,
  • Bing Wang,
  • Shenglin Ma,
  • Xueqin Chen,
  • Bing Xia

摘要

Background

Immunotherapy has become a primary treatment for advanced non-small cell lung cancer (NSCLC), although drug resistance is inevitable. Radiotherapy enhances immunotherapy efficacy, particularly in early to mid-stage NSCLC. However, the synergistic effects of radiotherapy and immunotherapy in advanced NSCLC remain controversial.

Methods

We retrospectively analyzed data from 141 stage IV NSCLC patients treated with first-line immunotherapy or chemoimmunotherapy at Hangzhou Cancer Hospital. Patients were divided into groups receiving radiotherapy combined with immunotherapy versus immunotherapy alone. Progression-free survival (PFS) and overall survival (OS) were evaluated using the Cox regression method. Subgroup Cox regression analyses were performed to optimize the combination regimens.

Results

The combined therapy group showed longer PFS (16.9 vs. 8.49 months, HR 0.57, p = 0.006) and OS (69.93 vs. 24.62 months, HR 0.60, p = 0.04). Subgroup analysis indicated that non-squamous NSCLC patients without immunotherapy rechallenge benefited most. Radiotherapy added to immunotherapy in lung or brain metastases showed a trend toward improved PFS (lung: 19.34 vs. 6.03 months, HR 0.62, p = 0.30; brain: 22.72 vs. 7.80 months, HR 0.59, p = 0.29). Concurrent (HR 0.41, p = 0.02) or consolidation radiotherapy (HR 0.32, p = 0.003) during immunotherapy offered greater PFS benefits than symptom-relief radiotherapy. Both stereotactic body radiotherapy and conventional radiotherapy yielded similar survival outcomes. Incidence of grade 3 or higher pneumonia post-lung-radiotherapy was 3.45%.

Conclusions

Our study highlights the synergistic efficacy of combining radiotherapy with immunotherapy in advanced NSCLC. Optimizing patient selection, targeting specific sites, effective timing, and tailored radiotherapy regimens significantly improved PFS and OS, providing crucial insights for enhancing clinical outcomes in advanced NSCLC.